{"nctId":"NCT00770133","briefTitle":"Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.","startDateStruct":{"date":"2010-02"},"conditions":["Allergic Conjunctivitis"],"count":141,"armGroups":[{"label":"Ketotifen/naphazoline","type":"EXPERIMENTAL","interventionNames":["Drug: Ketotifen/naphazoline"]},{"label":"Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle"]},{"label":"Naphazoline","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Naphazoline"]},{"label":"Ketotifen","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ketotifen"]}],"interventions":[{"name":"Ketotifen/naphazoline","otherNames":[]},{"name":"Naphazoline","otherNames":[]},{"name":"Ketotifen","otherNames":[]},{"name":"Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Positive history of ocular allergies and positive skin test reaction to cat hair, cat dander, grasses, ragweed, and/or trees within the past 24 months.\n* Calculated best-corrected visual acuity of 0.7 logMAR or better in each eye as measured using the ETDRS chart.\n* Positive bilateral conjunctival allergen challenge(CAC) reaction within 10 minutes of instillation of the last titration of allergen at visit 1.\n* Positive bilateral CAC reaction for at least 2 out of 3 time points at visit 2.\n\nExclusion Criteria:\n\n* Known contraindications or sensitivities to the study medication or its components.\n* Any ocular condition that, in the opinion of the investigator, could affect the subjects safety or trial parameters.\n* Use of disallowed medications during the period indicated prior to study enrollment or during the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ocular Itching","description":"Ocular itching was evaluated by the participant at 3, 5, and 7 minutes post challenge. Assessments were made using a 0-4 numerical analog scale, allowing 0.5-unit increments (but disallowing 0.25-unit increments), where: 0.0=None and 4.0=Incapacitating itch with an irresistible urge to rub","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"0.62"},{"groupId":"OG001","value":"0.40","spread":"0.65"},{"groupId":"OG002","value":"1.60","spread":"0.92"},{"groupId":"OG003","value":"1.81","spread":"0.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":"0.76"},{"groupId":"OG001","value":"0.59","spread":"0.79"},{"groupId":"OG002","value":"1.67","spread":"1.01"},{"groupId":"OG003","value":"1.96","spread":"0.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":"0.83"},{"groupId":"OG001","value":"0.56","spread":"0.87"},{"groupId":"OG002","value":"1.54","spread":"0.96"},{"groupId":"OG003","value":"1.84","spread":"1.01"}]}]}]},{"type":"PRIMARY","title":"Conjunctival Redness","description":"Conjunctival hyperemia was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were completed using a 0-4 numerical analog scale, allowing 0.5-unit increments, where: 0.0=None and 4.0=Extremely severe.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":"0.87"},{"groupId":"OG001","value":"1.49","spread":"0.83"},{"groupId":"OG002","value":"1.63","spread":"0.84"},{"groupId":"OG003","value":"2.06","spread":"0.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.13","spread":"1.00"},{"groupId":"OG001","value":"1.80","spread":"0.87"},{"groupId":"OG002","value":"1.69","spread":"0.89"},{"groupId":"OG003","value":"2.26","spread":"0.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.13","spread":"1.02"},{"groupId":"OG001","value":"1.88","spread":"0.89"},{"groupId":"OG002","value":"1.57","spread":"0.92"},{"groupId":"OG003","value":"2.18","spread":"0.85"}]}]}]},{"type":"SECONDARY","title":"Ciliary Redness","description":"Ciliary hyperemia (redness) was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were made using the same 0-4 scale, allowing 0.5-unit increments, where: 0.0=None and 4.0=Extremely severe.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":"0.86"},{"groupId":"OG001","value":"1.33","spread":"0.88"},{"groupId":"OG002","value":"1.49","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":"1.05"},{"groupId":"OG001","value":"1.76","spread":"0.91"},{"groupId":"OG002","value":"1.59","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.04","spread":"1.03"},{"groupId":"OG001","value":"1.76","spread":"0.94"},{"groupId":"OG002","value":"1.54","spread":"0.92"}]}]}]},{"type":"SECONDARY","title":"Episcleral Redness","description":"Episcleral hyperemia (redness) was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were made using the same 0-4 scale, allowing 0.5-unit increments, where: 0.0=None and 4.0=Extremely severe.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.91","spread":"0.89"},{"groupId":"OG001","value":"1.51","spread":"0.85"},{"groupId":"OG002","value":"1.65","spread":"0.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":"1.01"},{"groupId":"OG001","value":"1.76","spread":"0.88"},{"groupId":"OG002","value":"1.68","spread":"0.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":"1.03"},{"groupId":"OG001","value":"1.88","spread":"0.90"},{"groupId":"OG002","value":"1.60","spread":"0.94"}]}]}]},{"type":"SECONDARY","title":"Chemosis","description":"Chemosis was evaluated by the Investigator at 7, 15, and 20 minutes post challenge on a 0-4 numerical analog scale, allowing 0.5-unit increments, where: 0.0=None and 4.0=Extremely severe.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"0.33"},{"groupId":"OG001","value":"0.28","spread":"0.30"},{"groupId":"OG002","value":"0.39","spread":"0.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":"0.38"},{"groupId":"OG001","value":"0.46","spread":"0.47"},{"groupId":"OG002","value":"0.54","spread":"0.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":"0.41"},{"groupId":"OG001","value":"0.49","spread":"0.46"},{"groupId":"OG002","value":"0.54","spread":"0.58"}]}]}]},{"type":"SECONDARY","title":"Eyelid Swelling","description":"Lid swelling was evaluated by the participant at 7, 15, and 20 minutes post challenge on a 0-3 numerical analog scale, with 0.5-unit increments disallowed, where: 0.0=None and 3.0=Severe.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.4"},{"groupId":"OG001","value":"0.2","spread":"0.4"},{"groupId":"OG002","value":"0.2","spread":"0.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.5"},{"groupId":"OG001","value":"0.2","spread":"0.4"},{"groupId":"OG002","value":"0.2","spread":"0.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.5"},{"groupId":"OG001","value":"0.2","spread":"0.4"},{"groupId":"OG002","value":"0.2","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Eyes With hTearing","description":"Tearing was evaluated by the participant at 7, 15, and 20 minutes post challenge. Tearing was recorded as either absent or present.","paramType":"COUNT_OF_UNITS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Eyes With Ocular Mucus Discharge","description":"Ocular mucous discharge was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Mucous discharged was recorded as either absent or present.","paramType":"COUNT_OF_UNITS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":35},"commonTop":[]}}}